Central Nervous System Disorders Therapeutics Market, by Disease Type (Neurodegenerative Disorders {Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, and Others}, Infectious Diseases, Psychotic Disorders, Anxiety Disorders, Trauma, Mood Disorders, and Others), by Drug Class (Analgesics, Anti-cholinergic Agents, Anticonvulsants, Sedatives and Hypnotics, Antidepressants, Antipsychotics, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Nov 2021

Code : CMI4544

Pages :192

Formats :

Excel and PDF

Industry : Pharmaceutical

Central Nervous System Disorders Therapeutics MarketSize and Trends

The global central nervous system disorders therapeutics market is estimated to be valued at US$ 97,028.1 million in 2021 and is expected to exhibit a CAGR of 7.4% during the forecast period (2021-2028).

Figure 1.Global Central Nervous System Disorders Therapeutics Market Share (%) in Terms of Value, by Drug Class, 2021

Increasing prevalence of CNS disorders is expected to propel the growth of the global central nervous system disorders therapeutics market during the forecast period.

The increasing prevalence of CNS disorders is expected to propel the growth of the global central nervous system disorders therapeutics market during the forecast period. For instance, according to MedScape, a leading online global destination offering the latest medical news and expert perspectives, in 2019, the global prevalence of Parkinson’s disease was estimated to be 18-328 cases per 100,000 population per year. Moreover, according to the World Health Organization (WHO) report 2020, about 50 million people across the world were suffering from dementia in 2019. The same source reveals that approximately 10 million new cases of dementia are reported every year, out of which most of the cases are associated with Alzheimer’s disease.

Figure 2.Global Central Nervous System Disorders Therapeutics Market Share (%), by Distribution Channel, 2021

Rising number of product launches and approvals is expected to drive the growth of the global central nervous system disorders therapeutics market over the forecast period.

The rising number of product launches and approvals is expected to drive the growth of the global central nervous system disorders therapeutics market over the forecast period. For instance, in April 2020, Neurocrine Biosciences, Inc., a U.S.-based biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for its drug Ongentys, which is used to treat Parkinson’s disease.

Global Central Nervous System Disorders Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has affected the entire pharmaceutical industry supply chain, mainly due to the strict lockdown in various regions. However, demand for central nervous system disorders therapeutics is expected to increase during pandemic due to the association of neurological diseases (such as depression, anxiety and others) with COVID-19 infection. For instance, according to an article published in June 2021, in the journal Alzheimer's Research & Therapy, a study from the Cleveland Clinic, showed a close association between coronavirus genes and Alzheimer's disease. The study showed that SARSCoV2 infection resulted in multiple signaling pathways related to neuroinflammation and microvascular injury in the brain, which can also lead to cognitive decline.

Thus, impact of the Coronavirus (COVID-19) pandemic is expected to fuel growth of the global central nervous system disorders therapeutics market during the forecast period, owing to rising neurological disorders, as a result of COVID-19 infection during the pandemic.

According to the United Nations-Policy Brief: COVID-19 and the Need for Action on Mental Health published in May 2020, specific populations groups have been affected by COVID-19 in different ways. For instance, in Canada, 47% of health-care workers reported a need for psychological support. Moreover, in the People’s Republic of China, healthcare workers reported high rates of depression (50%), anxiety (45%), and insomnia (34%).